Covid-19

#Antibodies #Biopharmaceuticals #Biotherapeutics #Covid-19 #SARS-CoV-2

Helping Indian biotherapeutic companies advance novel therapeutics

Fusion Antibodies and BioTickle, its distributor in India, are providing local biopharmaceutical organisations with access to biopharmaceutical development capabilities. Since the emergence of Covid-19, Fusion Antibodies has contributed resources into developing a panel of unique protein antigens for use in discovery platforms. To date, the proteins have shown positive profiles… Read More

#News

#Covid-19 #Drug development #Drug discovery #Pharmaceuticals #RNA #SARS-CoV-2

SARS-CoV-2 spike protein induces lipid stripping from cell membrane

Scientists at the Institut Laue-Langevin (ILL), in collaboration with the Paul Scherrer Institut (PSI), the Institut de Biologie Structurale (IBS) and the Australian Nuclear Science and Technology Organisation (ANSTO), have published new data on how the SARS-CoV-2 spike protein interacts with mammalian lung cell membranes, allowing the viral… Read More

#Covid-19 #News #Trending News

#Covid-19 #Investment #Life sciences #Public health #Social enterprise

Mologic becomes a ‘social enterprise’ following acquisition

A group of philanthropic funds and investors led by the Soros Economic Development Fund (SEDF), with support from the Bill & Melinda Gates Foundation, has launched Global Access Health (GAH), a social enterprise that aims to expand access to affordable medical technology. The group has financed the acquisition of Mologic,… Read More

#News

#Covid-19 #Genomics #Infectious diseases #Therapeutics

Genomics analysis on why Covid-19 affects people so differently

Last year scientists from around the world undertook genetic analysis to uncover the genetic factors influencing why some Covid-19 patients develop severe, life-threatening disease requiring hospitalisation, while others escape with mild symptoms or none at all. A comprehensive summary of their findings to date, published in Nature, reveals 13 loci,… Read More

#Covid-19 #News #Trending News

#Covid-19 #Life sciences #Synthetic chemistry

£54 million project benefits pre-clinical discovery CRO

Loughborough’s life sciences hub Charnwood Campus in the UK has recommissioned its synthetic and chemistry research facility to cater to the needs of pre-clinical discovery contract research organisation (CRO) Charnwood Molecular. It will cost £54 million. The new laboratories will provide capacity for future growth and expansion of Charnwood Molecular’s medicinal chemistry… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Biotherapeutics #Covid-19 #Drug design #Drug development #Therapeutics

Exscientia accelerates Covid-19 drug discovery using AI

Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the Covid-19 Therapeutics Accelerator initiative, to progress a new class of Covid-19 therapeutics created using its artificial intelligence (AI) drug design platform. Exscientia has demonstrated proof-of-concept by using its AI platform… Read More

#News

#Cancer research #Covid-19 #Drug development #Drug discovery #Drug repurposing #Research

How this chemotherapy cancer drug can be used to fight Covid-19

Mount Sinai researchers have found that widely available and inexpensive drug targeting inflammatory genes have reduced morbidity and mortality in mice infected with SARS-CoV-2. Following its publication in Cell, and reporting by DDW, Megan Thomas spoke to Dr Ivan Marazzi, co-author of the study and associate professor in the Microbiology… Read More

#Editor's Choice #Exclusive Content #News

#Covid-19 #Drug delivery #Drug development #Drug discovery #Research

Academic investigates role of green tea compounds in Covid-19 drugs

University academic Dr Suresh Mohankumar has carried out research with colleagues in India during his time at JSS College of Pharmacy, JSS Academy of Higher Education and Research in Ooty prior to taking up his current role at Swansea University Medical School. Findings suggest that one of the compounds in… Read More

#News

#Awards #Clinical trials #Covid-19 #Data #Drug discovery #Immunology / Virology & Vaccines

Breakthrough Therapy Designation for single-shot chikungunya vaccine

Vaccine development company Valneva has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the US Food and Drug Administration (FDA). Breakthrough Therapy Designation intends to facilitate and expedite development and review of new drugs for serious or life-threatening conditions where preliminary clinical data demonstrates that… Read More

#Editor's Choice #News

#Anti-virals #Covid-19 #Drug development

Large-scale drug analysis reveals potential new Covid-19 antivirals

Researchers at the Francis Crick Institute and University of Dundee have screened thousands of drug and chemical molecules and identified a range of potential antivirals that could be developed into new treatments for Covid-19 or in preparation for future coronavirus outbreaks. While Covid-19 vaccines are being rolled out, there are… Read More

#Editor's Choice #News #Trending News

#Biopharmaceuticals #Biotechnology #Covid-19 #Health #Life sciences

UK pharma sees R&D spend hold up despite Brexit and Covid-19

A survey of 75 pharmaceutical, life sciences and medtech businesses indicates R&D spending is being maintained and is set to rise in 2021, despite Brexit and the impact of Covid-19. The survey included SMEs in these sectors in the UK and was conducted by accountancy group MHA. This is positive… Read More

#Business & Investment #News #Trending News #Trends & Analysis

#AI / data analytics / healthtech / informatics #Covid-19 #Data #Research

Industry report: Digital innovation and clinical trials

In the aftermath of Covid-19, ambitious strategies for digital transformation are seen as a wise investment as life sciences organisations upgrade their capacities for managing clinical trials and the scientific and regulatory data they generate. This is the key overall finding of the second annual TMF Futures survey of over… Read More

#Intelligence #Market Reports

#Covid-19 #Drug delivery #Drug development #Drug discovery #Life sciences #Regulatory #Technology

How will UK life sciences vision impact medicine development and research?

The new UK Life Sciences Vision, developed with businesses and experts in the field, outlines seven critical missions that government, industry, the NHS, academia and medical research charities will work together on at speed to solve – from cancer treatment to tackling dementia. These missions will focus on preventing, diagnosing,… Read More

#News #Regulatory #Trending News

#Covid-19 #Drug development #Drug discovery #Drug targets

Targeted treatments for respiratory infections

A new experimental model that more accurately replicates the impact of respiratory infections on the lungs and upper airways has been developed through an SME and academic partnership supported by the Infection Innovation Consortium (iiCON). Led by Founding Director, Professor Janet Hemingway CBE of Liverpool School of Tropical Medicine, iiCON… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #Vaccines

Moderna provides a clinical update on Delta variant immunity

Moderna has announced new results from in vitro neutralisation studies of sera from individuals vaccinated with the Moderna Covid-19 vaccine showing activity against variants of SARS-CoV-2. Vaccination with the Moderna Covid-19 vaccine produced neutralising titres against all variants tested, including additional versions of the Beta variant (B.1.351, first identified in… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #mRNA #Pfizer #Vaccines

The human touch: the benefits of real world evidence

Listen to this article on the DDW Podcast: Lu Rahman looks at the growing role of real world evidence and its benefits in the fight against Covid-19. Real world evidence (RWE)  is nothing new. While clinical trials have a significant part to play  - and indeed remain the ultimate standard for… Read More

#Business & Investment #Covid-19 #Editor's Choice #Exclusive Content #News